{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:35:51Z","timestamp":1770510951528,"version":"3.49.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,21]],"date-time":"2012-12-21T00:00:00Z","timestamp":1356048000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/2.5"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1007\/s40268-012-0002-4","type":"journal-article","created":{"date-parts":[[2013,2,25]],"date-time":"2013-02-25T17:20:56Z","timestamp":1361812856000},"page":"29-36","source":"Crossref","is-referenced-by-count":8,"title":["Bioequivalence and Pharmacokinetic Evaluation of Two Formulations of Risperidone 2\u00a0mg"],"prefix":"10.1007","volume":"13","author":[{"given":"Yun","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meng-qi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing-ying","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan-mei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang-yi","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shui-jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li-ping","family":"Weng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chen","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,21]]},"reference":[{"key":"2_CR1","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1517\/14656566.6.5.803","volume":"6","author":"HJ M\u00f6ller","year":"2005","unstructured":"M\u00f6ller HJ. Risperidone: a review. Expert Opin Pharmacother. 2005;6:803\u201318.","journal-title":"Expert Opin Pharmacother"},{"key":"2_CR2","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1097\/00004850-199503000-00003","volume":"10","author":"H He","year":"1995","unstructured":"He H, Richardson JS. A pharmacological, pharmacokinetic and clinical overview of risperidone, a new antipsychotic that blocks serotonin 5-HT2 and dopamine D2 receptors. Int Clin Psychopharmacol. 1995;10:19\u201330.","journal-title":"Int Clin Psychopharmacol"},{"key":"2_CR3","first-page":"S46","volume":"39","author":"D Keegan","year":"1994","unstructured":"Keegan D. Risperidone: neurochemical, pharmacologic and clinical properties of a new antipsychotic drug. Can J Psychiatry. 1994;39:S46\u201352.","journal-title":"Can J Psychiatry"},{"key":"2_CR4","doi-asserted-by":"crossref","first-page":"253","DOI":"10.2165\/00003495-199448020-00009","volume":"48","author":"S Grant","year":"1994","unstructured":"Grant S, Fitton A. Risperidone: a review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994;48:253\u201373.","journal-title":"Drugs"},{"key":"2_CR5","doi-asserted-by":"crossref","first-page":"538","DOI":"10.4088\/JCP.v58n1205","volume":"58","author":"SR Marder","year":"1997","unstructured":"Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58:538\u201346.","journal-title":"J Clin Psychiatry"},{"key":"2_CR6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/clpt.1993.146","volume":"54","author":"ML Huang","year":"1993","unstructured":"Huang ML, Van Peer A, Woestenborghs R, et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects. Chin Pharmacol Ther. 1993;54:257\u201368.","journal-title":"Chin Pharmacol Ther"},{"issue":"Suppl","key":"2_CR7","first-page":"13","volume":"55","author":"J Heykants","year":"1994","unstructured":"Heykants J, Huang ML, Mannens G, et al. The pharmacokinetics of risperidone in humans: a summary. J Clin Psychiatry. 1994;55(Suppl):13\u20137.","journal-title":"J Clin Psychiatry"},{"key":"2_CR8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JCP.0b013e3181c17df0","volume":"29","author":"M Hendset","year":"2009","unstructured":"Hendset M, Molden E, Refsum H, et al. Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone. J Clin Psychopharmacol. 2009;29:537\u201341.","journal-title":"J Clin Psychopharmacol"},{"key":"2_CR9","unstructured":"Risperidal\u00ae: package insert. Xi-an: Xian-Janssen Pharmaceutical Ltd., 2009."},{"key":"2_CR10","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0149-2918(03)80163-7","volume":"25","author":"EA Schaick van","year":"2003","unstructured":"van Schaick EA, Lechat P, Remmerie BM, et al. Pharmacokinetic comparison of fast-disintegrating and conventional tablet formulations of risperidone in healthy volunteers. Clin Ther. 2003;25:1687\u201399.","journal-title":"Clin Ther"},{"key":"2_CR11","doi-asserted-by":"crossref","first-page":"124","DOI":"10.5414\/CPP47124","volume":"47","author":"M C\u00e1novas","year":"2009","unstructured":"C\u00e1novas M, Delgadillo J, Torres F, et al. Bioequivalence evaluation of two strengths of risperidone tablet formulations in healthy volunteers. Int J Clin Pharmacol Ther. 2009;47:124\u201331.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2_CR12","unstructured":"World Medical Association. WMA Declaration Of Helsinki\u2014ethical principles for medical research involving human subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Ferney-Voltaire: WMA; 2000."},{"key":"2_CR13","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonised tripartite guideline: guideline for good clinical practice E6(R1). http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E6_R1\/Step4\/E6_R1__Guideline.pdf . Accessed 19 Nov 2012."},{"key":"2_CR14","unstructured":"State Food and Drug Administration. Guideline for good clinical principles [in Chinese]. http:\/\/www.sda.gov.cn\/WS01\/CL0053\/24473.html . Accessed 1 Dec 2009."},{"key":"2_CR15","unstructured":"Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry: bioanalytical method validation. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm070107.pdf . Accessed 19 Nov 2012."},{"key":"2_CR16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jchromb.2007.02.007","volume":"852","author":"B Cabovska","year":"2007","unstructured":"Cabovska B, Cox SL, Vinks AA. Determination of risperidone and enantiomers of 9-hydroxyrisperidone in plasma by LC\u2013MS\/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;852:497\u2013504.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2_CR17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jchromb.2007.08.007","volume":"858","author":"G Zhang","year":"2007","unstructured":"Zhang G, Terry AV Jr, Bartlett MG. Sensitive liquid chromatography\/tandem mass spectrometry method for the simultaneous determination of olanzapine, risperidone, 9-hydroxyrisperidone, clozapine, haloperidol and ziprasidone in rat brain tissue. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;858:276\u201381.","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"2_CR18","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3109\/03602538608998295","volume":"17","author":"RC Shumaker","year":"1986","unstructured":"Shumaker RC. PKCalc: a BASIC interactive computer program for statistical and pharmacokinetic analysis of data. Drug Metab Rev. 1986;17:331\u201348.","journal-title":"Drug Metab Rev"},{"key":"2_CR19","unstructured":"Center for Drug Evaluation, State Food and Drug Administration. Guideline for bioavailability and bioequivalence studies of generic drug products [in Chinese]. http:\/\/www.cde.org.cn\/zdyz.do?method=largePage&id=2066 . Accessed 1 Dec 2009."},{"key":"2_CR20","unstructured":"Center for Drug Evaluation and Research, US Food and Drug Administration. Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products\u2014general considerations. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM070124.pdf . Accessed 19 Nov 2012."}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40268-012-0002-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-012-0002-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-012-0002-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T18:12:28Z","timestamp":1551204748000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40268-012-0002-4"}},"subtitle":["An Open-Label, Single-Dose, Fasting, Randomized-Sequence, Two-Way Crossover Study in Healthy Male Chinese Volunteers"],"short-title":[],"issued":{"date-parts":[[2012,12,21]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["2"],"URL":"https:\/\/doi.org\/10.1007\/s40268-012-0002-4","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,21]]}}}